Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GNPX

Genprex Inc

Jun 13 • 04:00PM ET

0.2919

Dollar change -0.0212
Percentage change -6.77	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN SGMO CRBP ABEO IBIO MRKR BNTC VSTM INO

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.92	Insider Own	2.73%	Shs Outstand	29.01M	Perf Week	1.50%
Market Cap	8.47M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	28.22M	Perf Month	30.90%
Income	-19.38M	PEG	-	EPS next Q	-	Inst Own	1.46%	Short Float	8.81%	Perf Quarter	-19.65%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	18.02%	Short Ratio	0.54	Perf Half Y	-71.66%
Book/sh	0.16	P/B	1.82	EPS next Y	-	ROA	-205.73%	Short Interest	2.49M	Perf Year	-88.46%
Cash/sh	0.12	P/C	2.44	EPS next 5Y	-	ROE	-302.69%	52W Range	0.22 - 3.97	Perf YTD	-65.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	27.47%	ROIC	-501.16%	52W High	-92.65%	Beta	-0.40
Dividend TTM	-	Quick Ratio	1.94	Sales past 5Y	-	Gross Margin	-	52W Low	35.77%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	1.94	EPS Y/Y TTM	74.34%	Oper. Margin	-	RSI (14)	49.80	Volatility	4.80% 6.45%
Employees	15	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	92.96%	Payout	-	Rel Volume	0.16	Prev Close	0.31
Sales Surprise	-	EPS Surprise	0.00%	Sales Q/Q	-	Earnings	-	Avg Volume	4.63M	Price	0.29
SMA20	0.20%	SMA50	3.37%	SMA200	-55.93%	Trades		Volume	757,545	Change	-6.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-21	Initiated	National Securities	Buy	$7
Apr-29-19	Initiated	Noble Capital Markets	Outperform	$5

Jun-03-25 07:00AM	Genprex to Participate at BIO 2025 International Convention (PR Newswire) -10.16%
May-29-25 07:00AM	Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting (PR Newswire) +18.89%
May-28-25 07:00AM	Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting (PR Newswire)
May-07-25 07:00AM	Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes (PR Newswire)
May-06-25 07:00AM	Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma (PR Newswire) -5.68%
07:30AM	Loading…
Apr-30-25 07:30AM	Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting (PR Newswire)
Apr-29-25 07:30AM	Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting (PR Newswire)
Apr-28-25 07:30AM	Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma (PR Newswire)
Apr-24-25 08:15AM	Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting (PR Newswire) +14.62%
Apr-22-25 08:15AM	Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings (PR Newswire)
Mar-26-25 08:15AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting (PR Newswire)
Mar-25-25 08:15AM	Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions (PR Newswire)
Mar-04-25 08:15AM	Genprex to Participate at BIO Europe Spring 2025 (PR Newswire)
Feb-19-25 08:15AM	Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System (PR Newswire)
Feb-18-25 08:15AM	Genprex Provides Update on Diabetes Gene Therapy Program (PR Newswire) -7.01%
08:15AM	Loading…
Feb-13-25 08:15AM	Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer (PR Newswire)
Jan-24-25 07:28AM	Genprex doses first subject in expansion part of lung cancer gene therapy trial (Clinical Trials Arena)
Jan-23-25 08:00AM	Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa Gene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer (PR Newswire) -6.25%
Jan-14-25 09:28AM	Genprex Advances Cancer Trials and Diabetes Therapy (TipRanks)
Jan-06-25 09:15AM	Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-16-24 09:15AM	Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer (PR Newswire) -9.48%
Nov-21-24 10:16AM	Genprex links with University of Michigan on lung cancer treatment (Pharmaceutical Technology)
Nov-20-24 09:29AM	Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer (PR Newswire) -14.40%
Nov-05-24 09:29AM	Genprex Collaborators Present Positive Preclinical Data on Reqorsa Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting (PR Newswire) -10.40%
Oct-31-24 09:29AM	Genprex to Participate in 2024 BIO Europe Conference (PR Newswire) +11.39%
Oct-28-24 09:29AM	Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma (PR Newswire) +38.38%
Oct-24-24 09:29AM	Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive (PR Newswire) -19.25%
Oct-16-24 07:45AM	Genprex advances to highest dose in Phase I Acclaim-3 trial of Reqorsa (Clinical Trials Arena)
Oct-15-24 09:29AM	Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer (PR Newswire)
Oct-10-24 09:29AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (PR Newswire)
09:29AM	Loading…
Oct-07-24 09:29AM	Genprex Collaborators to Present Positive Preclinical Data on Reqorsa Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting (PR Newswire)
Sep-23-24 09:29AM	Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes (PR Newswire) +8.85%
Sep-19-24 09:29AM	Genprex Announces Formation of Mesothelioma Clinical Advisory Board (PR Newswire) +6.85%
Sep-09-24 09:29AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (PR Newswire)
Sep-04-24 09:29AM	Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes (PR Newswire) -19.70%
Sep-03-24 08:15AM	Genprex to Present and Participate at Upcoming September Investor and Industry Conferences (PR Newswire)
Aug-15-24 09:30AM	Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials (PR Newswire) -10.72%
Aug-14-24 09:25AM	Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer (PR Newswire) -14.11%
Aug-13-24 08:31AM	Genprex Granted Patent in Singapore for Reqorsa Gene Therapy with PD-1 Antibodies to Treat Cancers (PR Newswire) -32.52%
Aug-08-24 08:30AM	Genprex to Present at the August Sidoti Microcap Conference (PR Newswire)
Jun-27-24 08:31AM	Genprex Issues Stockholder Letter and Provides 2024 Corporate Update (PR Newswire)
May-30-24 08:31AM	Genprex to Present at the 2024 BIO International Convention (PR Newswire)
May-20-24 12:53PM	GNPX Stock Earnings: Genprex Beats EPS for Q1 2024 (InvestorPlace)
May-15-24 04:42AM	Genprex dosing subjects in trial of combination therapy for small-cell lung cancer (Clinical Trials Arena)
May-14-24 08:31AM	Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer (PR Newswire) +7.53%
May-13-24 08:31AM	Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors (PR Newswire)
May-08-24 06:08PM	Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner (PR Newswire) -6.05%
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) -5.13%
May-01-24 08:31AM	Genprex to Present and Participate at Upcoming May Investor and Industry Conferences (PR Newswire)
Apr-09-24 08:31AM	Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 08:57AM	Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up (Zacks)
Apr-03-24 08:31AM	Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer (PR Newswire) +9.51%
Apr-02-24 08:31AM	Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System (PR Newswire)
Mar-22-24 04:10PM	Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Mar-19-24 01:24PM	Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -17.36%
Mar-12-24 09:01AM	Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers (PR Newswire) -10.43%
Mar-06-24 08:30AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting (PR Newswire) +6.31%
Feb-07-24 08:15AM	Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators (PR Newswire) -11.17%
Feb-06-24 07:30AM	Genprex to Present at Upcoming BIO CEO & Investor Conference (PR Newswire) -10.45%
Feb-05-24 07:30AM	Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer (PR Newswire) +13.37%
Jan-31-24 08:42AM	Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 (PR Newswire) -29.13%
Jan-05-24 07:00AM	Genprex Provides Business Update and Outlook for 2024 (PR Newswire)
Nov-23-23 08:30AM	Genprex Granted Orphan Drug Designation in Small Cell Lung Cancer (NewMediaWire)
Nov-03-23 09:00AM	Genprex to Present at BIO-Europe 2023 (NewMediaWire) +27.29%
Nov-01-23 07:30AM	Genprex to Present at BIO-Europe 2023 Conference (PR Newswire)
Oct-20-23 03:00PM	Genprex Schedules, Hosts Virtual Key Opinion Leader Event (NewMediaWire)
07:30AM	Genprex to Host a Virtual Key Opinion Leader Event on 'Bringing Gene Therapy to the Fight Against Lung Cancers' (PR Newswire)
Oct-06-23 09:00AM	Genprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC Conference (NewMediaWire)
Oct-04-23 12:00PM	Genprex to Present Data on the Use of REQORSA for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) +5.11%
Sep-21-23 08:30AM	Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC (GlobeNewswire)
Sep-19-23 09:00AM	Genprex Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations (NewMediaWire)
Sep-08-23 08:00PM	Genprex to Present at Upcoming H.C. Wainwright Conference (NewMediaWire) +6.72%
Sep-07-23 07:30AM	Genprex to Present at Upcoming September Investor Conference (PR Newswire)
Sep-04-23 12:00PM	GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-01-23 09:20PM	Genprex Secures Patent Protection in 'Some of the Most Important Markets in the World' (NewMediaWire)
Aug-31-23 12:44AM	Genprex Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation (NewMediaWire)
Aug-24-23 12:25AM	Genprex Appoints Regulatory Expert as It Drives Clinical Programs Forward (NewMediaWire)
Aug-23-23 02:06AM	5 big analyst cuts: BofA sees 'increased risks' for Dick's Sporting Goods (Investing.com) -5.20%
Aug-22-23 07:30AM	Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs (PR Newswire) +7.86%
Aug-13-23 10:24AM	Genprex Granted FDA Orphan Drug Designation for REQORSA(R) for SCLC (NewMediaWire)
Aug-10-23 07:30AM	Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer (PR Newswire)
Aug-08-23 01:04AM	Genprex's Third Fast Track Designation Validates REQORSA(R)'s Potential (NewMediaWire)
Jul-28-23 08:00PM	Genprex Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China (NewMediaWire) +5.92%
Jul-25-23 01:22AM	Genprex Inc. Closes on $7.5M Registered Direct Offering (NewMediaWire)
Jul-21-23 04:15PM	Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -5.30%
12:57AM	Genprex Inc. Announces $7.5M Registered Direct Offering (NewMediaWire)
Jul-20-23 01:05AM	Genprex Enters Exclusive License Agreement with University of Pittsburgh (NewMediaWire)
Jul-19-23 08:00AM	Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -17.31%
12:37AM	Genprex Positioned to Expand Clinical Pipeline (NewMediaWire)
Jul-18-23 08:37AM	Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh (PR Newswire) +10.93%
Jul-12-23 01:00AM	Genprex Reports Positive Results From Phase 1 Acclaim-1 Clinical Trial (NewMediaWire) -8.95%
Jul-07-23 09:00PM	Genprex's Unique Treatment Paradigm Featured in Bell2Bell Podcast (NewMediaWire)
Jul-06-23 08:17AM	IBN Announces Latest Episode of The Bell2Bell Podcast featuring CEO Rodney Varner & CFO Ryan Confer of Genprex, Inc. (GlobeNewswire) -7.78%
12:51AM	Genprex Secures Chinese Patent, Exclusivity for REQORSA(R) Gene Therapy Combination (NewMediaWire)
Jul-05-23 08:35AM	Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers (PR Newswire)
Jun-29-23 09:03PM	Genprex Receives Fast Track Designation for Immunogene Therapy (NewMediaWire) +15.68%
Jun-28-23 08:35AM	Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer (PR Newswire) +6.50%
Jun-02-23 10:15AM	Genprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical Trial (ACCESSWIRE) +11.35%
Jun-01-23 11:59AM	Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study (Zacks) +8.45%
May-31-23 12:59AM	Genprex Receives Approval to Advance to Phase 2 of REQORSA(R) Trial (NewMediaWire) +7.22%

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GNPX

Genprex Inc

Upgrade your FINVIZ experience